Skip to content

Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00449345
Enrollment
150
Registered
2007-03-20
Start date
2007-05-31
Completion date
Unknown
Last updated
2007-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Tuberculosis Infection

Keywords

Latent tuberculosis infection, Health care workers, Tuberculin skin test, Mantoux skin test, Interferon gamma, Quantiferon, Cost effectiveness

Brief summary

The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable. In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays. In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers. We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.

Interventions

PROCEDUREBlood test for Quantiferon-GOLD assay

Sponsors

Maccabi Healthcare Services, Israel
CollaboratorOTHER
Assuta Hospital Systems
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Health care worker undergoing screening for LTBI

Exclusion criteria

* Previous tuberculosis or treatment for LTBI * Immunosuppressed due to drug treatment, HIV, organ transplant * Recent TB contacts

Countries

Israel

Contacts

Primary ContactDavid Shitrit, MD
david_s@mac.org.il+972 8 946 8617
Backup ContactBen Fox, MRCP
fox_b@mac.org.il+972 8 946 8617

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026